• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    A dermocosmetic aqueous base comprising, in addition to water, calcium chloride, potassium chloride, potassium phosphate, magnesium sulphate, sodium chloride, sodium hydrogencarbonate, sodium hydrogen phosphate, sodium citrate, citric acid, carnosine characterized in that it further contains 2-aminoenesulfinic acid.
    公开号:FR3072285A1
    申请号:FR1759589
    申请日:2017-10-12
    公开日:2019-04-19
    发明作者:Jean-Noel Thorel
    申请人:Jean-Noel Thorel；
    IPC主号:
    专利说明:

    AQUEOUS MINERALIZED SALINE SOLUTION WITH ANTIOXIDANT ACTIVITY, AND ITS USE IN DERMOCOSMETICS AND DERMOPHARMACY
    FIELD OF THE INVENTION
    The present invention relates to a saline and buffered aqueous solution, and to its cosmetic or dermopharmaceutical use. More specifically, the present invention relates to a mineralized aqueous base provided with antioxidant properties, improving the biomimicry of water with physiological cellular water of the dermis or biodermal water, in particular cutaneous cellular water, otherwise providing total or almost biomimicry total with the latter, and capable of effectively combating the processes of skin oxidation. The invention also relates to dermocosmetic compositions containing said aqueous base.
    STATE OF THE ART
    Today, in dermocosmetics, water, the main constituent of the living world and in particular of the human body, is considered as a simple excipient, making it possible to complete the formula of most cosmetic or dermo-pharmaceutical products with 100%. Consequently, only the bacteriological quality of the water used imports and is controlled. In practice, demineralized water is used.
    The present invention begins with the observation that the composition and / or properties of water, the main component of cosmetic and dermopharmaceutical products, do not entirely correspond to those of physiological cellular water from the dermis or biodermal water. Consequently, this water is not biocompatible with skin cells, in particular keratinocytes, so that it can, in certain cases, alter the different equilibria or cutaneous cell cycles.
    The thermal waters used in certain cosmetic or dermopharmaceutical preparations have biological properties, due to their particular content of metal ions or trace elements. However, they are not suitable due, in particular, to their redox potential or to their too high pH, or else to their too low or too high resistivity.
    In addition, demineralized thermal waters (for example, by treatment with an ion exchange system) have none of the properties of thermal waters from which they derive, since the content of trace elements and mineral salts in these waters has been reduced until it becomes negligible. In the context of the formulation of dermocosmetic products, it would therefore be preferable to use waters having a defined and biomimetic composition with the water of the skin cells.
    In parallel with the development of water with physicochemical characteristics similar to that of biodermal cellular water, it would be interesting to use, in dermocosmetics, water of isotonic formulation and capable of protecting the skin from the aggressions caused by external agents, including solar radiation and chemical and biological agents. These factors lead to the formation of free radicals within the skin, in particular ERO (reactive oxygen species) and ERN (reactive nitrogen species) very unstable molecules, having a very short half-life, nanosecond to millisecond order.
    EROs and ERNs are capable of damaging cellular structures (DNA, membranes, intracellular proteins) as well as extracellular (for example, components of the extracellular matrix such as collagen fibers). EROs also exert an indirect harmful action, by causing the oxidation of membrane lipids, which induces the formation of reactive carbonyl species, which contribute to amplify the tissue and cellular damage caused by EROs.
    The cells have defense systems against damage caused by free radicals, such as enzymes such as superoxide dismutase, catalase, lactoperoxidase, glutathione peroxidase and peroxyredoxin. However, in the event of overexposure to external aggressions, an imbalance is established between the deactivation of ERO and ERN and their formation. Exposure to ERO and ERN is directly linked to skin aging, loss of elasticity and radiance.
    It is known that the ability of the skin to protect itself from external aggressions, such as exposure to ultraviolet rays, pollution or other biological or chemical attacks, can depend in particular on its epidermal content of antioxidant substances capable of deactivating free radicals. It is therefore important to provide the human skin with sufficient antioxidants to promote the neutralization of ERO and ERN.
    Several approaches have been adopted to formulate biomimetic water in perfect affinity with skin water. By way of example, mention may be made of patent FR-A-2780887, which describes an aqueous saline and mineralized solution whose composition is determined to meet at least two bioelectric or bioelectronic parameters of the solution, one of which is redox potential, and the other of which is chosen between pH and resistivity. The choice and adjustment of the bioelectric or bioelectronic properties of water, allows us to approach the composition of the water contained in the skin cells. Consequently, the adaptation of these factors makes it possible to improve the biomimicry of the water of formulation configured with biodermal cellular water, and in particular physiological cutaneous cellular water.
    However, despite the presence of antioxidants, in small quantities, such as stable derivatives of vitamin C, the parameterized water described in this document does not effectively fight against the oxidation processes responsible for skin aging, or even the loss of radiance. Indeed, it is devoid of an effective antioxidant activity to fight against the deleterious effects induced by an imbalance of biological homeostasis vis-à-vis ERO and ERN, on the skin.
    DESCRIPTION OF THE INVENTION
    The problem which the invention proposes to solve is to develop a saline and mineralized aqueous solution, provided with effective antioxidant properties, so as to improve its biomimetism with biodermal cellular water, in particular physiological cellular water. cutaneous, or even be totally biomimetic with physiological cellular water, in particular physiological cutaneous cellular water.
    The present invention therefore relates to an aqueous dermocosmetic base, further comprising water; calcium chloride; potassium chloride; potassium phosphate; magnesium sulfate; sodium chloride; sodium hydrogencarbonate; sodium hydrogen phosphate; sodium citrate; citric acid; carnosine.
    The invention is characterized in that the aqueous dermocosmetic base additionally contains hypotaurine (2-aminoethanesulfmic acid).
    According to the invention, the water included in the base is advantageously demineralized water, preferably ultra pure water or milli-Q® water, the resisitivity of which is of the order of
    18.2 Megaohm (MQ) .cm.
    The present invention describes a composition which is similar to the composition of the intracellular and extracellular liquid phase, in terms of its salt composition and its bioelectric properties as defined in the present application. In addition, this composition is provided with antioxidant properties to counter the harmful effects of ERN and ERO.
    Surprisingly, the Applicant has demonstrated that the addition of organic antioxidants, in particular carnosine and hypotaurine, in a mineralized aqueous base as defined above, makes it possible to improve the affinity of said aqueous base with cells. skin.
    An aqueous solution according to the invention also exerts a bioregulatory activity vis-à-vis the skin cells.
    By various in vivo tests, it has also been observed that the aqueous base of the invention, in contact with the skin, contributes to improving the hydration effect, advantageously of an emulsion, while improving its appearance (flexibility and radiance) and thus act on skin aging.
    According to the present invention, the composition of the aqueous base is chosen to allow at least two bioelectric parameters to be adjusted, one of which is the redox potential, and the other of which is chosen between pH and resistivity, to have a value :
    - between 10 and 28, with regard to the redox potential
    - between 5 and 8, with regard to pH
    - and a resistivity substantially between 8000 ohms (Q) .cm and 80 Q.cm advantageously between 500 and 100 Q.cm.
    Advantageously, the composition of the aqueous base according to the invention is chosen so that the osmotic pressure of said base is between 70 and 1500 mOsmole, and preferably between 200 and 400 mOsmole, for example between 280 and 320 mOsmole.
    Advantageously, the composition of the aqueous base is determined so as to obtain the abovementioned values for the three bioelectric parameters of the solution respectively the redox potential, the pH and the resistivity. The aqueous base can therefore comprise, for example, adjuvants or buffers making it possible to adjust or adjust its pH.
    Carnosine is a dipeptide of β-alanine and Lhistidine. In humans, high concentrations of this compound are found in muscle tissue and the brain. Preferably, a pure or highly purified form of carnosine is used in the aqueous base according to the invention. Preferably, carnosine is obtained by chemical synthesis. By way of example, there may be mentioned the cosmetic Dragosine corresponding to the name INCI carnosine and marketed by the company SYMRJSE.
    According to one aspect of the invention, carnosine represents between 0.0001% and 1% by weight of the aqueous base, advantageously between 0.001% and 1%.
    2-aminoethanesulfmic acid, more commonly known as hypotaurine, is a sulfinic acid intermediate in the biosynthesis of taurine. Like the latter, it acts in humans as an endogenous neurotransmitter on specific channel receptors of pentameric structure, permeable to Cf ions, the main agonist of which is glycine. In practice, a pure or highly purified form of hypotaurine can be used. Preferably, hypotaurine is obtained by chemical synthesis. By way of example, mention may be made of the hypotaurine cosmetic raw material corresponding to the name INCI aminoethanesulfmic acid and marketed by the company DKSH.
    According to one aspect of the invention, hypotaurine represents between 0.0001% and 1% by total weight of the aqueous base, advantageously between 0.001% and 1%.
    In a particular embodiment, the aqueous base according to the invention comprises:
    From 0.000001% to 0.1% by total weight of the aqueous base of calcium chloride, advantageously from 0.0001% to 0.1%;
    From 0.0001% to 0.1% by total weight of the aqueous base of potassium chloride, advantageously from 0.001% to 0.1%;
    From 0.00001% to 0.1% by total weight of the aqueous potassium phosphate base, advantageously from 0.0001% to 0.1%;
    From 0.0001% to 0.1% by total weight of the aqueous base of magnesium sulfate, advantageously from 0.001% to 0.1%;
    From 0.001 to 4% by total weight of the aqueous base of sodium chloride, advantageously from 0.1 to 4%;
    From 0.0001 to 0.1% by total weight of the aqueous base of sodium hydrogencarbonate;
    From 0.0001% to 0.1% by total weight of the aqueous base of sodium hydrogen phosphate;
    From 0.0001% to 1% by total weight of the aqueous citric acid base, advantageously from 0.001% to 1%;
    From 0.001% to 1% by total weight of the aqueous base of sodium citrate;
    From 0.0001% to 1% by total weight of the aqueous carnosine base, advantageously from 0.001% to 1%;
    From 0.0001 to 1% by total weight of the aqueous base of 2-aminoethanesulfinic acid, advantageously from 0.001 to 1%.
    Any aqueous base, according to the invention, behaves like the water used in the composition of the physiological water of the skin cells, in particular of the epidermis.
    The term “biomimetic” denotes the capacity of any aqueous base, according to the invention, to exercise the biomechanical, biophysical, physiological or biological function or activity of the physiological water of the skin cells. In particular, the skin as a living biological medium cannot distinguish between its own cellular water and any aqueous base according to the invention.
    By "biodermal water" or "skin cell water" is meant physiological water, that is to say, water present in the intracellular or extracellular compartments of skin cells. Thus, biodermal water shares the bioelectric properties of water in the human body. Advantageously, it comprises all the components or products entering into the composition of the physiological water of the skin cells, in particular of the epidermis.
    In this context, it is understood that this element is considered in an isolated state, in a form identical to its natural form, or modified compared to its natural form, but remaining cytocompatible, whatever its mode of production or production. , in particular by separation from living skin products, by biosynthesis, by a biotechnological process, or even by genetic recombination.
    Consequently, "biodermal water" or "skin cell water" has a good affinity with the skin and is perfectly biocompatible with the latter, it respects both the internal and external environment of cells, in particular skin cells.
    According to a particular embodiment, the aqueous base according to the invention comprises hyaluronic acid. Preferably, it is a low molecular weight hyaluronic acid between 20 and 50 kDa.
    Low molecular weight hyaluronic acid regulates hydration and limits insensitive water loss by strengthening the tight junctions between keratinocytes in the epidermis. It also stimulates the synthesis of collagen I within the dermis. As an example, we can cite the raw material Primalhyal 50, corresponding to the designation INCI Hydrolyzed hyaluronic acid, and marketed by the company GIVAUDAN.
    In practice, hyaluronic acid, preferably hydrolyzed hyaluronic acid, represents between 0.01% and 1% by total weight of the aqueous base, advantageously between 0.1% and 0.5%.
    The aqueous base according to the invention can also comprise preservatives. Any preservative capable of being used in cosmetic compositions can be used in the formulation of the aqueous base according to the invention.
    Advantageously, the preservatives used are alkanediols, even more advantageously 1,2-alkanediols or 1,3-alkanediols, and their mixtures.
    In a particular embodiment, the preservative is a 1,2-diol chosen from 1,2pentanediol, 1,2-hexanediol, 1,2-heptanediol, 1,2-octanediol and 1,2-decanediol and their mixtures.
    In another embodiment, the preservative is a 1,3-diol chosen from 1,3propanediol and 1,3-butanediol, and their mixtures.
    In practice, these alkanediols are marketed by several companies, notably the company SYMRISE or MINACARE.
    According to the invention, the aqueous base comprises between 0.01 and 20% by total weight of diols as preservatives, preferably between 0.1% and 10%, advantageously between 0.5% and 5%.
    In another embodiment, the aqueous base according to the invention is devoid of preservatives but sterilized by irradiation, ultrafiltration, pasteurization before or after packaging of the product according to methods known to the skilled person.
    The present invention also relates to a cosmetic or personal hygiene composition, or one for dermopharmaceutical use, comprising at least 40% by total weight of the composition, or even at least 50%, or even at least 70%, if not 100%, of a aqueous base according to the invention, as defined above.
    The invention also relates to a cosmetic or personal hygiene composition comprising the aqueous base according to the invention, in particular monophasic, biphasic or even three-phase, for example a water in oil (W / O) emulsion, or oil in water (O / W) ) or a gel, or a two-phase composition containing the aqueous phase according to the invention, a fatty phase and devoid of emulsifiers or gelling agents.
    In a particular embodiment, the cosmetic or personal hygiene composition consists of 100% by total weight of the aqueous base according to the invention and is a sprayable composition (spray). This product can be sprayed directly on the skin surface to hydrate, refresh or even improve the bioavailability of the active ingredients contained in another cosmetic product applied to the skin beforehand (for example, an anhydrous product).
    In a particular embodiment, the cosmetic or personal hygiene composition containing the aqueous base according to the invention is a gel.
    In a particular embodiment, the cosmetic or personal hygiene composition containing the aqueous base according to the invention is an O / W emulsion.
    In a particular embodiment, the cosmetic or personal hygiene composition containing the aqueous base according to the invention is a lotion.
    The cosmetic or personal hygiene or dermopharmaceutical composition containing the aqueous base according to the invention therefore generally has a primary function and a secondary function.
    The primary function is both to protect and maintain, even to restore biological and physiological cutaneous homeostasis, and to create an appropriate stable dosage form (milk, cream, etc.). The secondary function consists in treating the skin by providing it with one or more benefits topically, notably therapeutically. It can for example be an antioxidant activity to fight against skin aging, the formation of wrinkles, loss of elasticity and / or radiance of the skin.
    Advantageously, the cosmetic or personal hygiene composition, or for dermopharmaceutical use, containing the aqueous base according to the invention contains other active agents or excipients, capable of improving the biomimicry of the aqueous base with respect to water. contained in skin cells or, to obtain other desired cosmetic or dermatological effects.
    In a particular embodiment, the composition comprising the aqueous base according to the invention also contains active principles capable of improving skin hydration.
    In a particular embodiment, the cosmetic or personal hygiene composition, or for dermopharmaceutical use containing the aqueous base according to the invention comprises an apple seed extract, optionally supplemented with vitamin B3 (niacinamide or vitamin PP) or its derivatives. Apple seed extract (Pyrus malus) increases the synthesis of several aquaporins. Aquaporins are proteins that play a key role in balancing skin hydration.
    Vitamin PP and its derivatives work by stimulating the activity of the serine palmitoyl transferase, an enzyme involved in the synthesis of sphingosine, a precursor molecule of ceramides and therefore, improve the barrier function of the skin and fight dry skin.
    Preferably, the apple seed extract is an extract of lipophilic nature. In practice, the EDERLINE S cosmetic raw material, corresponding to the INCI designation Hexyldecanol & butylene glycol & Pyrus malus (apple) seed extract, or the EDERLINE LS raw material, corresponding to the INCI designation hexyldecanol & Pyrus malus (apple) seed extract & brassica campestris (rapeseed) sterols & tocopherol, can be used as a source of apple seed extract. As for the niacinamide raw material, it is marketed by QUIMICA MASSO and corresponds to the INCI niacinamide designation.
    Advantageously, the composition containing the aqueous base according to the invention comprises between 0.001 and 1% of plant extract of P. malus and / or from 0.001 to 10% of niacinamide by total weight of the composition.
    In another embodiment, the cosmetic or personal hygiene composition, or for dermopharmaceutical use, containing the aqueous base according to the invention comprises an extract of the Imperata cyliridrica plant, preferably a root extract, advantageously titrated in aquaporins . Indeed, the incorporation of extracts from 7. cylindrica in the composition comprising the aqueous base according to the invention makes it possible to improve the hydration of the stratum corneum.
    In practice, the raw material MOIST 24 PH corresponding to the designation INCI Imperata cylindrica root extract & water & glycerin & PEG-8 & carbomer & (and) phenoxyethanol & sodium citrate & potassium sorbate & citric acid and sold by the company SEDERMA can be used in the context of the present invention. Advantageously, the composition containing the aqueous base according to the invention comprises between 0.001 and 1% by weight of said composition of plant extract of ’/. cylindrica, advantageously between 0.01 and 0.1%.
    In another embodiment, the cosmetic or personal hygiene composition, or for dermopharmaceutical use containing the aqueous base according to the invention further comprises, a bioactive system combining on the one hand, a stable form in aqueous solution of a nucleotide chosen from ΓΑΤΡ (adenosine triphosphate) Gp4G (diguanosine tetraphosphate) and Ap4A (diadenosine tetraphosphate); and on the other hand, at least one biomimetic peptide comprising at most six amino acids, mimicking a skin polypeptide or a skin protein, or an agonist or antagonist biomolecule of said peptide or said protein. In practice, the combination of these active ingredients makes it possible to catalyze the metabolic activity of skin cells while obtaining a dermocosmetic or therapeutic effect through the use of biomimetic peptides. The latter can be selected in order to obtain the desired effect, for example, an effect of inhibiting irritations of neurogenic origin, a depigmenting activity, an effect inhibiting any intolerance or sensitization etc.
    In practice, in the bioactive system according to the invention, the nucleotide represents at most 10% by total weight of the composition, preferably between 0.001% and 5%; and the biomimetic peptide represents between 0.001% to 1% by total weight of the composition.
    The cosmetic or personal hygiene composition, or for dermopharmaceutical use, containing the aqueous base according to the invention can also comprise the usual adjuvants in the field under consideration, such as hydrophilic or lipophilic thickeners or gelling agents, hydrophilic or lipophilic additives, active ingredients, in particular cosmetics, preservatives, antioxidants, perfumes, fillers, pigments, UV filters, odor absorbers, dyes, moisturizers, vitamins, essential fatty acids, liposoluble polymers, in particular hydrocarbons, opacifiers, stabilizers, sequestrants, conditioners and propellants.
    Of course, a person skilled in the art will take care to choose this or these optional adjuvants or excipients, and / or their quantity, in such a way that the advantageous properties of the composition according to the invention are not, or not substantially, affected by the proposed addition.
    The invention also relates to the use of an aqueous base as defined above, for the manufacture and / or obtaining of a stable topical dosage form, in particular monophasic, diphasic, or triphasic, for cosmetic or personal hygiene, or for dermo-pharmaceutical use.
    By galenical form is meant any topical form or presentation allowing the interactive cutaneous base to play a functional activity with respect to the skin.
    The manner in which the invention can be carried out and the advantages which ensue therefrom will emerge more clearly from the following exemplary embodiments, given by way of non-limiting indication.
    EXAMPLES
    Example 1: Aqueous base - Spraying
    Ingredient <> Water Qsp 100 propanediol 0.50 Sodium citrate 0.46 Hydrolyzed hyaluronic acid 0.10 Sodium chloride 0.10 Citric acid 0.07 2- aminoethanesulfmic acid 0.05 carnosine 0.05 Glucose 0.05 mannitol 0.05 Sodium hydrogen phosphate 0.048
    Calcium potassium chloride 0.04 Sodium hydrogen carbonate 0,035 Calcium chloride 0.0121 Magnesium sulfate 0.01 Potassium phosphate 0.006
    Example 2: Aqueous base - Gel
    Ingredient% Water Qsp 100 dimethicone 6.50 Methylsilanol mannuronate 3.20 Glycerin 3.00 Isononyl isononanoate 3.00 propanediol 3.00 hexyldecanol 2.45 betaine 2.00 Butylene glycol 1.50 Dipropylene glycol 1.50 polyacrylamide 1.20 Pentylene glycol 1.00 methylPropanediol 0.80 Cl3-14 isoparaffin 0.72 Acrylates / Cl0-30 alkyl acrylate copolymer 0.50 Dimethicone / vinyl copolymerdimethicone 0.50 Sodium citrate 0.46 1,2-hexanediol 0,455 Caprylyl glycol 0.35
    carnosine 0.254943 Sodium chloride 0.25 Silica 0.20 Laureth-7 (INCI) 0.18 Citric acid 0.07 2- aminoethanesulfmic acid 0.05 Propylene glycol 0.046958 adenosine 0.04 Potassium chloride 0.04 Gum-4 Biosaccharide 0,036 Sodium hydrogen carbonate 0,035 Pyrus malus (apple) seed extract (INCI) 0,025 Brassica campestris (rapeseed) sterols (INCI) 0.02 Sodium hydrogen phosphate 0.0125 Magnesium sulfate 0.01 Potassium phosphate 0.006 tocopherol 0.005 Calcium chloride 0.0006 Brilliant blue FCF (CI 42090) 0.00003
    Example 3: Aqueous base - Cream
    lii "i'êdien (Water Qsp 100 dimethicone 7.25 propanediol 5.00 Methylsilanol mannuronate 3.20 Butylene glycol 3.00
    Ethylhexyl palmitate 3.00 Glycerin 3.00 hexyldecanol 2.45 Steareth-2 (INCI) 2.40 Boron nitride 2.00 undecane 1.94901 Steareth-21 (INCI) 1.60 Cetyl alcohol 1.50 tridecane 1.05 Pentylene glycol 1.00 methylpropanediol 0.80 polyacrylamide 0.80 Dimethicone / vinyl copolymerdimethicone 0.75 Acryl / c copolymer 10-30 alkyl acrylate 0.50 Cl3-14 isoparaffin 0.48 Sodium citrate 0.46 1,2-hexanediol 0,455 Caprylyl glycol 0.35 carnosine 0.254511 Sodium chloride 0.25 Laureth-7 (INCI) 0.12 Citric acid 0.07 2- aminoethanesulfmic acid 0.05 Ceramide NP 0.05 Propylene glycol 0.042854 adenosine 0.04 Potassium chloride 0.04
    Gum-4 Biosaccharide 0,036 Sodium hydrogen carbonate 0,035 Pyrus malus (apple) seed extract (INCI) 0,025 Brassica campestris (rapeseed) sterols (INCI) 0.02 Sodium hydrogen phosphate 0.0125 Magnesium sulfate 0.01 Potassium phosphate 0.006 tocopherol 0.0059 Calcium chloride 0.0006 Helianthus annuus (sunflower) seed oil (INCI) 0.00009
    Example 4 Process for Formulating the Aqueous Base
    1- Weighing water in a beaker;
    2- Add one by one of the constituents of the formula with stirring until complete solubilization;
    3- Stopping the agitation and controlling the parameters of the composition according to the invention.
    权利要求:
    Claims (13)
    [1" id="c-fr-0001]
    1 / Dermocosmetic aqueous base, comprising, in addition to water, calcium chloride, potassium chloride, potassium phosphate, magnesium sulfate, sodium chloride, sodium hydrogencarbonate, hydrogen phosphate sodium, sodium citrate, citric acid, carnosine characterized in that it also contains 2-aminoethanesulfinic acid.
    [2" id="c-fr-0002]
    2 / aqueous base according to claim 1, characterized in that the carnosine represents between 0.0001% and 1% by weight of the base, advantageously between 0.001% and 1%.
    [3" id="c-fr-0003]
    3 / Aqueous base according to claim 1 or 2, characterized in that the 2 aminoethanesulfinic acid represents between 0.0001% and 1% by weight of the base, advantageously between 0.001% and 1%.
    [4" id="c-fr-0004]
    4 / aqueous base according to any one of the preceding claims, characterized in that it further comprises hyaluronic acid having a molecular weight of between 20 and 50 kDa, preferably hydrolyzed hyaluronic acid.
    [5" id="c-fr-0005]
    5 / aqueous base according to claim 4, characterized in that the hyaluronic acid represents between 0.01% and 1% by weight of the base, advantageously between 0.1% and 0.5%.
    [6" id="c-fr-0006]
    6 / aqueous base according to any one of the preceding claims, characterized in that the composition of said aqueous base is chosen to allow at least two bioelectric parameters to be adjusted, one of which is the redox potential, and the other of which is chosen between pH and resistivity, to have a value:
    - between 10 and 28, with regard to the redox potential
    - between 5 and 8, with regard to pH
    - between 8000 Ohms.cm and 80 Ohms.cm as regards the resistivity, advantageously between 500 and 100 Ohms.cm
    [7" id="c-fr-0007]
    7 / aqueous base according to any one of the preceding claims, characterized in that its composition is chosen so that the osmotic pressure of said base is between 70 and 1500 mOsmole, and preferably between 200 and 400 mOsmole, for example between 280 and 320 mOsmole.
    [8" id="c-fr-0008]
    8 / aqueous base according to any one of the preceding claims, characterized in that it further comprises:
    From 0.000001% to 0.1% by total weight of the calcium chloride base, advantageously from 0.0001% to 0.1%;
    From 0.0001% to 0.1% by total weight of the potassium chloride base, advantageously from 0.001% to 0.1%;
    From 0.00001% to 0.1% by total weight of the potassium phosphate base, advantageously from 0.0001% to 0.1%;
    From 0.0001% to 0.1% by total weight of the magnesium sulphate base, advantageously from 0.001% to 0.1%;
    From 0.001 to 4% of by total weight of the sodium chloride base, advantageously from 0.1 to 4%;
    From 0.0001 to 0.1% by total weight of the sodium hydrogencarbonate base;
    From 0.0001% to 0.1% by total weight of the sodium hydrogen phosphate base;
    From 0.0001% to 1% by total weight of the citric acid base, advantageously from 0.001% to 1%;
    From 0.001% to 1% by total weight of the sodium citrate base;
    From 0.0001% to 1% by total weight of the base of camosine, advantageously from 0.001% to 1%;
    From 0.0001 to 1% by total weight of the 2-aminoethanesulfinic acid base, advantageously from 0.001 to 1%.
    [9" id="c-fr-0009]
    9 / Cosmetic or personal hygiene composition, or for dermopharmaceutical use, characterized in that it comprises 40% by total weight, or even at least 50%, or even at least 70%, of an aqueous base, as defined in any of the preceding claims.
    [10" id="c-fr-0010]
    10 / Composition according to claim 9, characterized in that it is an O / W emulsion, a W / O emulsion, a gel, a lotion or a sprayable composition.
    [11" id="c-fr-0011]
    11 / Composition according to one of claims 9 or 10, characterized in that it comprises an extract of the roots of the Imperata cylindrica plant, between 0.001 and 1% by total weight of the composition, more preferably between 0.01 and 0.1%.
    [12" id="c-fr-0012]
    12 / Composition according to one of claims 9 to 11, characterized in that it comprises an extract of the plant Pyrus malus, between 0.001 and 1% by total weight of the composition.
    [13" id="c-fr-0013]
    13 / Use of an aqueous base according to claims 1 to 8, for the manufacture and / or obtaining of a stable topical galenic form, in particular monophasic, diphasic, or triphasic, for cosmetic use or personal hygiene, or for dermo-pharmaceutical use.
    类似技术:
    公开号 | 公开日 | 专利标题
    EP1112057B1|2007-03-14|Cosmetic or dermopharmaceutical use of peptides for healing, hydrating and improving skin appearance during natural or induced ageing |
    FR3072285B1|2019-09-27|AQUEOUS SALINE MINERALIZED AND PROVIDED WITH ANTIOXIDANT ACTIVITY, AND ITS USE IN DERMOCOSMAL AND DERMOPHARMACY
    FR2980362A1|2013-03-29|NOVEL COSMETIC USE OF ALBIZIA JULIBRISSIN EXTRACT AND CORRESPONDING TOPICAL COMPOSITION
    KR20060028401A|2006-03-29|Compositions and methods for treatment of rosacea
    WO1998009611A1|1998-03-12|Cosmetic use of compounds with lipoaminoacid structure and cosmetic compositions with soothing activity incorporating some of these compounds
    EP1575605B1|2011-04-13|Cosmetic or pharmaceutical composition comprising peptides with the sequence arg-gly-ser
    EP1581177A2|2005-10-05|Cutaneous metabolic bio-activator
    FR2849381A1|2004-07-02|Cosmetic or dermatological skin-treatment composition, useful e.g. for sun-tanning, comprises a complex of an endonuclease with a nucleotide or nucleic acid
    EP1792608B1|2014-06-18|Composition in the form of an oil-in-water emulsion and its cosmetic uses
    KR20070112289A|2007-11-22|Methods and compositions for preventing and treating aging or photodamaged skin
    KR20170099656A|2017-09-01|Cosmetic compositions for moisturizing
    EP1874328A1|2008-01-09|Use of a peptide in the form of a slimming active principle
    FR2849375A1|2004-07-02|Cosmetic or dermatological skin-treatment composition, useful e.g. for protection against light-induced aging, comprises a complex of a peptide or protein with a nucleotide or nucleic acid
    EP2026879B1|2016-03-30|Use of peptides as active slimming ingredients
    FR2858769A1|2005-02-18|Cosmetic, dermatological and/or pharmaceutical compositions, especially for combating skin aging and/or protecting skin, containing peptide including arginine-glycine-serine moiety as active agent
    WO2008015344A2|2008-02-07|Dermatological and/or cosmetic composition containing polypeptides or peptides of the protein slc24a5
    KR20180003870A|2018-01-10|Cosmetic compositions for moisturizing
    EP2705050B1|2016-02-24|Novel peptides that are modulators of the protein trf2 and compositions containing same
    FR2849377A1|2004-07-02|Cosmetic or dermatological skin-treatment composition, useful e.g. for regulating the skin flora, comprises a complex of a specific peptide or protein with a nucleotide or nucleic acid
    FR2997853A1|2014-05-16|Reducing or delaying the thinning of skin and the sagging of skin and stimulating cellular metabolism of keratinocytes, comprises applying effective quantity of an extract of Myrothamnus flabellifolia to skin
    FR3112941A1|2022-02-04|Cosmetic or dermatological treatment based on peptide| of the skin and its appendages
    KR20220020564A|2022-02-21|A functional micro-n-recovery cosmetic composition for effective skin regeneration and anti-aging comprising microneedle, low molecular weight peptide and natural extracts
    FR2871688A1|2005-12-23|METHOD FOR PROMOTING THE PENETRATION OF AN ACTIVE INGREDIENT AND COMPOSITION FOR ITS IMPLEMENTATION
    FR3101544A1|2021-04-09|COSMETIC OR DERMATOLOGICAL TREATMENT BASED ON PEPTIDE | OF THE SKIN AND ITS PHANERES
    WO2010072929A1|2010-07-01|Soothing cosmetic or pharmaceutical composition comprising a peptide which activates hmg-coa reductase
    同族专利:
    公开号 | 公开日
    FR3072285B1|2019-09-27|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    FR2780887A1|1998-07-08|2000-01-14|Jean Noel Thorel|AQUEOUS SALINE AND MINERALIZED SOLUTION, AND ITS USE IN COSMETICS AND DERMOPHARMACY|FR3107186A1|2020-02-19|2021-08-20|Claire BIANCHIN|NEW COSMETIC AND / OR DERMATOLOGICAL COMPOSITION WITH OSMOTIC SYNERGY AND RELATED MANUFACTURING PROCESS|
    FR3112475A1|2020-07-20|2022-01-21|Naos Institute Of Life Science|ecobiological formulation, compatible with cellular life, usable in the cosmetic, dermopharmaceutical or veterinary fields|
    FR3112480A1|2020-07-20|2022-01-21|Naos Institute Of Life Science|Aqueous composition having trophic properties with respect to skin cells and capable of facilitating the formulation of cosmetic or veterinary products|
    法律状态:
    2018-10-27| PLFP| Fee payment|Year of fee payment: 2 |
    2019-04-19| PLSC| Publication of the preliminary search report|Effective date: 20190419 |
    2019-10-30| PLFP| Fee payment|Year of fee payment: 3 |
    2020-10-29| PLFP| Fee payment|Year of fee payment: 4 |
    2021-10-28| PLFP| Fee payment|Year of fee payment: 5 |
    优先权:
    申请号 | 申请日 | 专利标题
    FR1759589|2017-10-12|
    FR1759589A|FR3072285B1|2017-10-12|2017-10-12|AQUEOUS SALINE MINERALIZED AND PROVIDED WITH ANTIOXIDANT ACTIVITY, AND ITS USE IN DERMOCOSMAL AND DERMOPHARMACY|FR1759589A| FR3072285B1|2017-10-12|2017-10-12|AQUEOUS SALINE MINERALIZED AND PROVIDED WITH ANTIOXIDANT ACTIVITY, AND ITS USE IN DERMOCOSMAL AND DERMOPHARMACY|
    [返回顶部]